

Publications of PD Dr. med. habil. Ramona Erber (2022-01-23)

A: Research articles

First / senior author:

1. Impact of spatially heterogeneous Trop-2 expression on prognosis in oral squamous cell carcinoma
Erber R, Spoerl St, Mamilos A, Krupar R, Hartmann A, Ruebner R, Taxis J, Wittenberg M, Reichert TE, Spanier G*, Silvia Spoerl*
International Journal of Molecular Sciences 2021 2021 Dec 22;23(1):87
*contributed equally
2. Variable expression of the disialoganglioside GD2 in breast cancer molecular subtypes
Erber R, Kailayangiri S, Huebner H, Ruebner M, Hartmann A, Häberle L, Meyer J, Völkl S, Mackensen A, Landgraf L, Schulz-Wendtland R, Beckmann MW, Fasching PA, Farwick N, Rossig C, Gass P
Cancers 2021, 13(21), 5577. <https://doi.org/10.3390/cancers13215577>
3. MET Amplification in Non-Small Cell Lung Cancer (NSCLC) — A Consecutive Evaluation Using Next- Generation Sequencing (NGS) in a Real-World Setting
Schubart C, Stöhr R, Tögel L, Fuchs F, Sirbu H, Seitz G, Seggewiss-Bernhardt R, Leistner R, Sterlacci W, Vieth M, Seidl C, Mugler M, Kapp M, Hohenforst-Schmidt W, Hartmann A, Haller F, **Erber R**
Cancers 2021 13, 5023. <https://doi.org/10.3390/cancers13195023>
4. Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer — A Europe-Wide External Quality Assessment
Erber R, Hartmann A, Fasching PA, Ruebner M, Stöhr R, Beckmann MW, Zentgraf M, Popp V, Weidler J, Simon I, Becker S, Huebner H, Fischer J, Guerini Rocco E, Viale G, Cayre A, Penault-Llorca F, Caniego Casas T, Pérez-Miés B, Palacios J, Jank P, Denkert C, Khoury L, Mairinger T, Ferrazzi F
Cancers 2021 2021 Sep 21;13(18):4718. doi: 10.3390/cancers13184718
5. PIWI-like 1 and PIWI-like 2 expression in breast cancer
Erber R, Meyer J, Taubert H, Fasching PA, Wach S, Häberle L, Gaß P, Schulz-Wendtland R, Landgraf L, Olbricht S, Jung R, Beckmann MW, Hartmann A, Rübner M
Cancers (Basel) 2020 Sep 24;12(10):E2742. doi: 10.3390/cancers12102742.
6. Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
Erber R, Rübner M, Davenport S, Hauke S, Beckmann MW, Hartmann A, Häberle L, Gass P, Press MF, Fasching PA
Breast Cancer Res Treat 2020 Aug 27. doi: 10.1007/s10549-020-05865-2. Online ahead of print.
7. Prominent entrapment of respiratory epithelium in primary and metastatic intrapulmonary non-epithelial neoplasms: a frequent morphological pattern closely mimicking adenofibroma and other biphasic pulmonary lesions
Erber R, Haller F, Hartmann A, Agaimy A
Virchows Archiv 2020 Aug;477(2):195-205. doi: 10.1007/s00428-020-02796-7. Epub 2020 Mar 19.

8. BAP1 loss is a useful adjunct to distinguish malignant mesothelioma including the adenomatoid-like variant from benign adenomatoid tumors
Erber R, Warth A, Muley T, Hartmann A, Herpel E, Agaimy A
Applied Immunohistochemistry & Molecular Morphology 2020 Jan;28(1):67-73.
doi: 10.1097/PAI.0000000000000700.
9. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer
Fasching PA, Gass P, Häberle L, Volz B, Hein A, Hack CC, Lux MP, Jud SM, Hartmann A, Beckmann MW, Slamon DJ, **Erber R**
Breast Cancer Research and Treatment 2019 Jun;175(3):617-625. doi:
10.1007/s10549-019-05198-9. Epub 2019 Mar 13.
10. Misses and near misses in diagnosing nodular fasciitis and morphologically related reactive myofibroblastic proliferations: experience of a referral center with emphasis on frequency of USP6 gene rearrangements.
Erber R, Agaimy A
Virchows Arch. 2018 Sep;473(3):351-360. doi: 10.1007/s00428-018-2350-0. Epub 2018 Apr 5.
11. Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer.
Erber R, Stöhr R, Herlein S, Giedl C, Rieker RJ, Fuchs F, Ficker JH, Hartmann A, Veltrup E, Wirtz RM, Brueckl WM
Anticancer Res. 2017 Dec;37(12):6771-6778. DOI: 10.21873/anticancerres.12137
12. Predictive role of HER2/neu, Topoisomerase-II-alpha and Tissue Inhibitor of Metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate risk breast cancer: results from the WSG-AGO EC-Doc Trial
Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A.
Breast Cancer Res Treat. 2015 Apr;150(2):279-88. doi: 10.1007/s10549-015-3310-x. Epub 2015 Feb 28

First author, contributed equally:

1. Targeted sequencing of FH-deficient uterine leiomyomas reveals biallelic inactivating somatic fumarase variants and allows characterization of missense variants
Popp B*, **Erber R***, Kraus C, Vasileiou G, Hoyer J, Burghaus S, Hartmann A, Beckmann MW, Reis A, Agaimy A
Modern Pathology 2020 Jul 1. doi: 10.1038/s41379-020-0596-y. Online ahead of print.
*contributed equally
2. TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients – First Results on the Influence of Tumor-Infiltrating Lymphocytes
Würfel F*, **Erber R***, Huebner H, Hein A, Lux MP, Jud S, Kremer AN, Kranich H, Mackensen A, Häberle L, Hack C, Rauh C, Wunderle M, Gaß P, Rabizadeh S, Brandl A-L, Langemann H, Volz B, Nabieva N, Schulz-Wendtland R, Dudziak D, Beckmann MW, Hartmann A, Fasching PA*, Rübner M*
Breast Care 2018;13:8-14; <https://doi.org/10.1159/000486949>;
*contributed equally

3. Fumarate hydratase (FH) deficiency in uterine leiomyomas: recognition by histological features versus blind immunoscreening.
Siegler L*, **Erber R***, Burghaus S, Brodkorb T, Wachter W, Wilkinson N, Bolton J, Stringfellow H, Haller F, Beckmann MW, Hartmann A, Agaimy A.
Virchows Arch. 2018 Jan 13. doi: 10.1007/s00428-018-2292-6.
*contributed equally

Koautorenschaften:

1. Superpixel Pre-Segmentation of HER2 Slides for Efficient Annotation; Öttl M, Mönius J, Marzahl C, Rübner M, Geppert CI, Hartmann A, Beckmann MW, Fasching PA, Maier A, **Erber R**, Breininger K;
arXiv:2201.07572; accepted for BVM Workshop 2022, Springer, Informatik aktuell.
2. Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma
Christgen M, [...], **Erber R**, [...], Kreipe H;
The Journal of Pathology: Clinical Research 2021 J Pathol Clin Res. 2021 Dec 10. doi: 10.1002/cjp2.253. Epub ahead of print. PMID: 34889530.
3. Kang EY, Millstein J, Popovic G, [...], **Erber R**, [...], Köbel M. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. **Virchows Arch.** 2021 Nov 15. doi: 10.1007/s00428-021-03232-0.
4. Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments
Gstotberger F, Brandl C, Wendland K, Petkovic S, Emmerich C,
Erber R, Geppert C, Hartmann A, Andreas Mackensen A, Nitschke L, Müller F
International Journal of Molecular Sciences 2021, 22, 10433. <https://doi.org/10.3390/ijms221910433>
5. Mammographic density and prognosis in primary breast cancer patients
Heindl F, Fasching PA, Hein A, Hack CC, Heusinger K, Gass P, Pöschke P, Stübs FA, Schulz-Wendtland R, Hartmann A, **Erber R**, Beckmann MW, Meyer J, Häberle L, Jud SM, Emons J
The Breast <https://doi.org/10.1016/j.breast.2021.06.004>
6. Tumour-Infiltrating Inflammatory Cells in Early Breast Cancer: An Underrated Prognostic and Predictive Factor?
Schnellhardt S, **Erber R**, Büttner-Herold M, Rosahl M-C, Ott OJ, Strnad V, Beckmann MW, King L, Hartmann A, Fietkau R, Distel L
International Journal of Molecular Sciences 2020, 21, 8238;
doi:10.3390/ijms21218238
7. HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment
Wuerfel F, Huebner H, Häberle L, Gass P, Hein A, Jud SM, Hack CC, Wunderle M, Schulz-Wendtland R, **Erber R**, Hartmann A, Ekici A, Beckmann MW, Fasching P, Rübner M
Scientific Reports 2020 Sep 25;10(1):15750. doi: 10.1038/s41598-020-72837-3.
8. Is Ovarian Tissue Transport at Supra-zero Temperatures Compared to Body Temperature Optimal for Follicle Survival?
Bleisinger N, Dittrich R, Orłowski P, Tischer H, Söder S, **Erber R**, Hoffmann I, Beckmann MW, Lotz L
In Vivo (2020) 34 (2), 533-541

9. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicenter study from the Ovarian Tumor Tissue Analysis Consortium
The Authors/Members of the Ovarian Tumor Tissue Analysis (OTTA) Consortium: Martins FC, Couturier D-L, [...], **Erber R**, [...], Brenton JD
British Journal of Cancer 2020 Jun 18, 123, 793–802. doi: 10.1038/s41416-020-0900-0. Online ahead of print.
10. Accelerated Partial Breast Irradiation: Macrophage Polarisation Shift Classification Identifies High-Risk Tumours in Early Hormone Receptor-Positive Breast Cancer.
Schnellhardt S, **Erber R**, Büttner-Herold M, Rosahl M-C, Ott OJ, Strnad V, Beckmann MW, King L, Hartmann A, Fietkau R, Distel L
Cancers 2020, 14 February 2020, 12, 446; doi:10.3390/cancers12020446
11. Discrimination Analysis of Breast Calcifications using X-Ray Dark-Field Radiography.
Rauch T, Rieger J, Pelzer G, Horn F, **Erber R**, Wunderle M, Emons J, Nabieva N, Fuhrich N, Michel T, Hartmann A, Fasching P, Anton G
Medical Physics 2020 Jan 24. doi: 10.1002/mp.14043.
12. Nuclear NR4A3 Immunostaining is a Specific and Sensitive Novel Marker for Acinic Cell Carcinoma of the Salivary Glands
Haller F, Skálová A, Ihrler S, Märkl B, Bieg M, Moskalev EA, **Erber R**, Blank S, Winkelmann C, Hebele S, Baněčková M, Wiemann S, Müller S, Zenk J, Eils R, Iro H, Hartmann A, Agaimy, A
The American Journal of Surgical Pathology: May 13, 2019 - Volume Publish Ahead of Print - Issue - p doi: 10.1097/PAS.0000000000001279
13. Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
Gass P, Lux MP, Rauh C, Hein A, Bani MR, Fiessler C, Hartmann A, Häberle L, Pretscher J, **Erber R**, Wachter DL, Schulz-Wendtland R, Beckmann MW, Fasching PA, Wunderle M.
BMC Cancer December 2018 18(1); DOI: 10.1186/s12885-018-4925-1
14. Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians.
Gass P, Untch M, Müller V, Möbus V, Thomssen C, Häberle L, **Erber R**, Hein A, Jud SM, Lux MP, Hack CC, Hartmann A, Kolberg HC, Ettl J, Lüftner D, Jackisch C, Beckmann MW, Janni W, Schneeweiss A, Fasching PA, Nabieva N
Geburtshilfe Frauenheilkd. 2018 Jul;78(7):707-714. doi: 10.1055/a-0642-9462. Epub 2018 Jul 25.
15. BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients
Wunderle M, Gass P, Häberle L, Flesch VM, Rauh C, Bani MR, Hack CC, Schrauder MG, Jud SM, Emons J, **Erber R**, Ekici AB, Hoyer J, Vasileiou G, Kraus C, Reis A, Hartmann A, Lux MP, Beckmann MW, Fasching PA, Hein A.
Breast Cancer Res Treat. 2018 Aug;171(1):85-94. doi: 10.1007/s10549-018-4797-8. Epub 2018 May 3.
16. Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS)

Gebrekidan MT, **Erber R**, Hartmann A, Fasching PA, Emons J, Beckmann MW, Braeuer A

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818782532. doi:

10.1177/1533033818782532.

17. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma: A monocentric clinicopathologic analysis.

Haderlein M, Scherl C, Semrau S, Lettmaier S, Hecht M, **Erber R**, Iro H, Fietkau R, Agaimy A.

Strahlenther Onkol. 2017 Nov;193(11):961-970. doi: 10.1007/s00066-017-1196-8.

Epub 2017 Aug 21.

18. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial

Gluz O*, Liedtke C*, Huober J, Peyro-Saint-Paul H, Kates R, Kreipe HH, Hartmann A, Pelz E, **Erber R**, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Harbeck N on behalf of the EC-Doc investigators (West German Study Group/AGO-B).

Ann Oncol. 2016 Feb 18; 27(6): 1035-1040. doi: 10.1093/annonc/mdw070

19. Fibroblast Growth Factor Receptor (FGFR) amplifications are rare events in bladder cancer.

Fischbach A, Rogler A, **Erber R**, Stoehr R, Poulson R, Heidenreich A, Schneevoigt BS, Hauke S, Hartmann A, Knuechel R, Veeck J, Gaisa NT.

Histopathology 2015 Apr;66(5):639-49. doi: 10.1111/his.12473. Epub 2015 Jan 12

20. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, **Erber R**, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2014 Aug;25(8):1551-7. doi: 10.1093/annonc/mdu186. Epub 2014 May 14.

B: Case Reports

1. DICER1-mutated botryoid fibroepithelial polyp of the parotid duct: Report of the first case

Erber R, Preidl R, Stoehr R, Haller F, Hartmann A, Kesting M, Agaimy A

Head and Neck Pathology 2021 Jul 19. doi: 10.1007/s12105-021-01364-y

2. Adenomatoid Tumor of the Uterus: A Report of 6 Unusual Cases With Prominent Cysts Including 4 With Diffuse Myometrial Involvement, 4 With Uterine Serosal Involvement, and 2 Presenting in Curettage Specimens

Lerias S, Ariyasriwatana C, Agaimy A, **Erber R**, Young RH, Oliva E

International Journal of Gynecological Pathology 2020 Sep 4. doi:

10.1097/PGP.0000000000000685. Online ahead of print.

3. Identification and characterization of a *GLMN* splice site variant in a family with glomuvenous malformations

Skowronek D, Hebebrand M, **Erber R**, Agaimy A, Zweier C, Felbor U, Rath M

European Journal of Dermatology 2020 Apr 1;30(2):179-181. doi:
10.1684/ejd.2020.3716.

4. Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver – case report and review of literature
Zundler S*, **Erber R***, Agaimy A, Hartmann A, Kiesewetter F, Strobel D, Neurath M, Wildner D
BMC Cancer. 2016 Feb 20;16(1):130. doi: 10.1186/s12885-016-2184-6.
*contributed equally

C: Geladene Reviews

1. Pathologie ausgewählter epithelialer Neoplasien der Brust – Teil 1
Erber R, Grasruck K, Fabienne Lange, Hartmann A, Schulz-Wendtland R, Preuß C, Wunderle M, Jud SM, Fasching PA, Beckmann MW, Hack CC
Frauenheilkunde up2date 2021; 15: 415-432, DOI 10.1055/a-1305-0071
2. Pathologie ausgewählter epithelialer Neoplasien der Brust – Teil 2
Erber R, Grasruck K, Fabienne Lange, Hartmann A, Schulz-Wendtland R, Preuß C, Wunderle M, Jud SM, Fasching PA, Beckmann MW, Hack CC
Frauenheilkunde up2date 2021; 15: 435-452, DOI 10.1055/a-1364-0952
3. Understanding PD-L1 Testing in Breast Cancer – a Practical Approach
Erber R, Hartmann A
Breast Care 6 October 2020, DOI: 10.1159/000510812
4. Leitlinienbasierte Aufarbeitung und Befundung von Lymphonodektomiepräparaten und Sentinel-Lymphknoten gynäkologischer Malignome
Höhn AK, Brambs CE, **Erber R**, Hiller R, Mayr D, Schmidt D, Schmoeckel E, Horn L-C
Der Pathologe, 22 July 2020, <https://doi.org/10.1007/s00292-020-00805-9>
5. Histology of Luminal Breast Cancer
Erber R, Hartmann A
Breast Care 2020;15:327–336, <https://doi.org/10.1159/000509025>
6. Das un- und dedifferenzierte Endometriumkarzinom - Eine seltene Entität mit breitem differenzialdiagnostischem Spektrum
Höhn AK, Brambs CE, Opitz S, **Erber R**, Hartmann A, Horn L-C
Der Pathologe 2019 40:609–618, 2019 Oct, <https://doi.org/10.1007/s00292-019-00670-1>
7. Mammakarzinom: Neuerungen in Früherkennung und Diagnostik (CME-Fortbildung)
Wunderle M, Schneider MO, Brandl A-L, **Erber R**, Balbach E, Hartmann A, Schulz-Wendtland R, Jud SM, Lux MP, Rauh C, Hack CC, Beckmann MW, Heindl F
Frauenheilkunde up2date 2019; 13 (1): 39–57, DOI: 10.1055/a-0639-9419
8. TILGen-Studie – Immunologische Angriffspunkte bei Patientinnen mit Brustkrebs - Einfluss der Tumor-infiltrierenden Lymphozyten
Erber R, Hartmann A, Beckmann MW, Mackensen A, Kremer A, Reimann H, Hübner H, Hein A, Lux MP, Jud S, Häberle L, Gaß P, Volz B, Schulz-Wendtland R, Rübner M, Fasching PA
Der Pathologe, 39(2), 236-240 DOI 10.1007/s00292-018-0526-7 2018 Nov
9. Risk, Prediction and Prevention of Hereditary Breast Cancer – Large-Scale Genomic Studies in Times of Big and Smart Data

Wunderle M, Olmes G, Nabieva N, Häberle L, Jud SM, Hein A, Rauh C, Hack CC, **Erber R**, Ekici AB4, Hoyer J, Vasileiou G, Kraus C, Reis A, Hartmann A, Schulz-Wendtland R, Lux MP, Beckmann MW, Fasching PA
Geburtshilfe Frauenheilkd. 2018 May; 78(5): 481–492. Published online 2018 Jun 4. doi: [10.1055/a-0603-4350]

D: Geladene Buchbeiträge

1. Konservative Tumorthherapie bei Mammakarzinom – Kapitel (Erber): Tumorbologie des primären Mammakarzinoms
Liedtke, Cornelia and Jens-Uwe Blohmer (Eds.), **Erber** (Co-author)
Berlin, Boston: **DeGruyter-Verlag**, 03/2020
2. **WHO Classification of Tumours Editorial Board. Female genital tumours.** Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol. 4). <https://publications.iarc.fr/592>.
Chapter 16.0.0.11: Hereditary leiomyomatosis and renal cell carcinoma (Responsible author: Erber R)